<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Implementation of the Medical devices and In-vitro diagnostic medical devices Regulations (debate) - Thursday, 25 October 2018</title><meta name="title" content="Verbatim report of proceedings - Implementation of the Medical devices and In-vitro diagnostic medical devices Regulations (debate) - Thursday, 25 October 2018" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2018 - Source: European Parliament" /><meta name="available" content="25-10-2018" /><meta name="sipade-leg" content="8" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Implementation of the Medical devices and In-vitro diagnostic medical devices Regulations (debate) - Thursday, 25 October 2018" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-8-2018-10-25-ITM-007_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-8-2018-10-25-ITM-007_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2018-10-25-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2018-10-25-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2018-10-25-ITM-006_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2018-10-25-ITM-006_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-8-2018-10-25-ITM-008_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-8-2018-10-25-ITM-008_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2018-10-25_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2018-10-25_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2018/2790(RSP)">2018/2790(RSP)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">O-000085/2018</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/O-8-2018-000085_EN.html" class="ring_ref_link">O-000085/2018</a><span class="ring_ref_nolink"> (B8-0416/2018)</span><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-8-2018-10-25-ITM-007_EN.html" class="ring_ref_link">PV 25/10/2018 - 7</a><br />
                        <a class="ring_ref_selected">CRE 25/10/2018 - 7</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p></td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p></td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Thursday, 25 October 2018 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 7. Implementation of the Medical devices and In-vitro diagnostic medical devices Regulations (debate)</td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:02:02&amp;playerEndTime=20181025-10:01:00" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:02:02&amp;playerEndTime=20181025-10:01:00" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:02:02&amp;playerEndTime=20181025-10:01:00" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table align="right" cellpadding="0" cellspacing="0"><tr><td><a href="/doceo/document/PV-8-2018-10-25-ITM-007_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_left.gif" width="22" height="20" border="0" alt="" /></a></td><td class="switch_button_pv_cre"><a href="/doceo/document/PV-8-2018-10-25-ITM-007_EN.html" title="Minutes">PV</a></td><td><a href="/doceo/document/PV-8-2018-10-25-ITM-007_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_right.gif" width="5" height="20" border="0" alt="" /></a></td></tr></table></td></tr></table>
<a name="4-011-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96952.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:02:02&amp;playerEndTime=20181025-09:02:14" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">La Présidente. – </span></span>  L’ordre du jour appelle le débat sur la question avec demande de réponse orale à la Commission sur la mise en œuvre des règlements relatifs aux dispositifs médicaux et aux dispositifs médicaux de diagnostic in vitro posée par Mairead McGuinness, Biljana Borzan, Boleslaw G. Piecha, Gesine Meissner, Kateřina Konečnà, Margrete Auken, Piernicola Pedicini, Joëlle Mélin, au nom de la commission de l’environnement, de la santé publique et de la sécurité alimentaire (<a href="/doceo/document/O-8-2018-000085_EN.html">O-000085/2018</a> – B8-0416/2018) (<a href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2018/2790(RSP)">2018/2790(RSP)</a>).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-012-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28115.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:02:14&amp;playerEndTime=20181025-09:05:26" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mairead McGuinness, </span></span>  <span class="italic">author</span><span class="bold">.</span> – Madam President, this is a really important debate. I think sometimes people might think we legislate and then forget, but actually this debate is about making sure that the legislation on medical devices is implemented in full, and on time. But the reason it has been tabled – and I thank the colleagues who have co-signed with me, we were all involved in this legislation – is that concerns are being raised about the timely implementation. </p>
<p class="contents">Let’s reflect on why we had to modernise this law. It was because there were scandals in the medical devices sector, some of a criminal nature, and some identifying problems with how the industry is regulated, the ‘fit-for-purpose’ of notified bodies being one particular issue. So the reason we ask this question is because those concerns on implementation are being raised, but our focus is on patient safety and making sure that there is a supply of devices that are scrutinised fully so that there is no interruption in the medical care and attention that our patients receive. </p>
<p class="contents">Can I say that I have a friend going in next week for a knee operation. They are not worried about the gadget, or the knee, because they presume it is going to be safe and effective, and that they will come out skipping, and I hope they will. They are worried just about the operation. I think when patients go into hospital and have a procedure involving a medical device they presume that the medical device is certified and fit for purpose – and we have to give them that guarantee, and that’s the purpose of our question to you this morning. </p>
<p class="contents">We are concerned about the Commission’s coordination. There are three different, if you like, DGs of the Commission involved in this, so how is that working, and is it effective? And also, when we were debating this legislation, Brexit wasn’t a reality. It now is, and we have to take account of the implications and consequences of Brexit on the medical device legislation and on the supply of devices that keep our patients safe. </p>
<p class="contents">One of the issues that has been raised with us is the expertise available both perhaps within the Commission itself, but also within Member States and within notified bodies, and of the notified bodies that currently operate. I would like the Commission to clarify how many have actually looked for re-designation, as is required under this legislation. I understand it takes 18 months to re-designate a notified body, and if many have not applied at this stage, then we need to know that they will immediately and that they will be certified in time to meet the strict requirements of this legislation. </p>
<p class="contents">Lastly, are Member States doing enough? Because they are the ones who are perhaps raising this issue with us as well as the industry, and what do they need to do to make sure that they get this in place in their Member State and on time? Thank you, Commissioner, for taking the question. I look forward to your responses.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-013-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:05:33&amp;playerEndTime=20181025-09:10:51" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elżbieta Bieńkowska,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Madam President, thank you very much for this question as it allows me to update you on the state of play of the implementation of the two regulations on medical devices. I know this is an extremely important issue. We all want the continuous availability of safe and innovative medical devices and, of course, for this we need a smooth transition to the new system.</p>
<p class="contents">Let me underline, at the very beginning, that so far all relevant legal deadlines established by the regulations have been met. Work is advancing and progressing according to the plans. This was the case for the establishment of the governance structure; the launch of the designation code and procedure for notified bodies; and the delivery of the new plan for the implementation of the new medical devices database (EUDAMED).</p>
<p class="contents">We had already prepared for the future even before the regulations were adopted. We established effective cooperation with the national competent authorities for medical devices. Together with them, we have elaborated a roadmap of activities to be undertaken during the transitional period. Work is on track to implement the roadmap, again together with the expert groups. We are in continuous dialogue with the notified bodies, industry and all other relevant stakeholders. </p>
<p class="contents">As was said in the speech by Ms McGuinness, there are three directorates—general cooperating and sharing responsibilities. We are putting a lot of human resources on this file. But let me assure you, we have a very common understanding of the topic and of the issues between our Commission services. Also, Member States have mobilised their resources to contribute to the implementation process and Member States are fully committed, in the form of the competent authorities for medical devices, to preparing for the future.</p>
<p class="contents">We are aware that we need enough notified bodies by the end of the transition period. This is a key precondition for the smooth transition. The Commission has set up the entire legal and technical infrastructure to allow for the designation procedure to start as soon as possible. Again, I want to underline that we have been ready from the very first legal date, which was 27 December last year. The number of applications received so far shows that the designation procedure is overall on track. </p>
<p class="contents">So far, there have been no delays in assessing the applications of notified bodies. But of course we should not only look at the numbers. The top priority is patient safety. So we should remember that the lack of effective control of the notified bodies under the old system was one of the main reasons to review the medical devices framework. A large share of the responsibility now lies with the notified bodies themselves, as well as with the operators. It is also up to them to prepare and prove their fitness under the revised framework. </p>
<p class="contents">A few words on Brexit as it is an extremely important issue. As for all other sectors, this is also a challenge for the medical devices industry. So far, four notified bodies have been established in the UK. In its public notice of January this year, the Commission advised stakeholders to take all necessary measures because, as we all know, a certificate issued by UK notified bodies will no longer be valid as from 29 March next year. </p>
<p class="contents">Many other sectors, of course, face the same situation, but, as far as we know, the UK notified bodies and industry associations have been extremely active in preparing for Brexit ahead of time. Four notified bodies have already taken the initiative to adapt to the post—Brexit scenario. Again, we should not rest on our laurels, but for now, we see that they were very proactive and active.</p>
<p class="contents">So let me conclude by saying that we are on track. There are no deviations from the requirements and deadlines established by Parliament and the Council. So for now, there is no reason to ring the alarm bell. But of course there is still a lot of work ahead of us: first to ensure the transition to the new system but also the availability of devices over the next few years. Therefore, we in the Commission, together we will monitor the implementation process in very close and very constant cooperation with the national competent authorities, the Member States of course, and all other stakeholders.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-014-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112748.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:11:02&amp;playerEndTime=20181025-09:14:11" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Biljana Borzan, </span></span>  <span class="italic">u ime kluba S&amp;D</span><span class="bold">.</span> – Gospođo predsjedavajuća, svrha Regulative o medicinskim uređajima i <span class="italic">in vitro</span> dijagnostičkim uređajima je da europskim pacijentima omogući pristup sigurnim i učinkovitim uređajima, te povrati povjerenje u europsku proizvodnju nakon skandala s umjetnim kukovima i umecima za grudi. Komisija je inicijalni prijedlog objavila još 2012. godine, trijalozi su završeni 2016. godine. Regulative su stupile na snagu 2017., s tranzicijskim razdobljem od tri godine za medicinske uređaje i pet godina za <span class="italic">in vitro</span> dijagnostičke uređaje. Cijenjeni kolegice i kolege, trebamo imati na umu da se na ovim novim pravilima radilo čak šest godina.</p>
<p class="contents">Danas raspravljamo o problemima u implementaciji novih pravila, jer naime može se dogoditi da do početka primjene sustav ne bude spreman i da se obustavi opskrba medicinskim uređajima. Najveći problem je prilagodba imenovanih tijela, na kojima počiva cijeli sustav stavljanja uređaja na tržište. Ta tijela procjenjuju zadovoljavaju li medicinski i <span class="italic">in vitro</span> uređaji specifikacije i propise prije nego što uđu u prodaju i upotrebu. Proces njihovog ratificiranja teče mnogo sporije nego što bi trebao, prema podacima iz svibnja ove godine, od 59 postojećih imenovanih tijela, samo njih 30 je pokrenulo postupak recertifikacije, a taj postupak traje 18 mjeseci. </p>
<p class="contents">Ukoliko se nešto ne promijeni, moguće je da će u svibnju 2020., kada završava prijelazno razdoblje, postojati ozbiljan manjak certifikacijskih kapaciteta. Situaciju naravno dodatno komplicira Brexit, jer se u Velikoj Britaniji vrši znatan broj certifikacija za tržište Europske unije. No, to nije jedini problem - Komisija je od potrebnih 18 implementacijskih akata, u trenutku pisanja ovog usmenog pitanja, objavila njih samo nekoliko. Nadalje, nije jasno hoće li sustav EUDAMED, koji je ključan za funkcioniranje sustava, biti operativan na vrijeme.</p>
<p class="contents">Gospođo povjerenice, bilo mi je drago čuti danas vaše optimistične najave i iskreno se nadam da će sve ono što ste rekli i biti primijenjeno, međutim shvatite i našu zabrinutost. Moram reći da nisam sklona ponovnom otvaranju regulativa kako bi se produžili rokovi i prijelazno razdoblje. Trebamo imati na umu da je rad na ovim zakonima počeo još davne 2012., te da je Parlament trijalozima već pristao na produljenje rokova. Naši građani zaslužuju najkvalitetniju uslugu i zbog toga je vrlo teško objasniti zašto ovo sve toliko dugo traje i nadam se da će sve ono što je danas od strane Komisije izgovoreno biti provedeno u djelo. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-015-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96870.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:14:13&amp;playerEndTime=20181025-09:19:43" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gesine Meissner, </span></span>  <span class="italic">im Namen der ALDE-Fraktion</span><span class="bold">.</span> – Frau Präsidentin, Frau Kommissarin, liebe Kolleginnen und Kollegen! Das ist ja fast wie ein Familientreffen zu <span class="italic">medical devices</span> nach den ganz langen und zähen Verhandlungen, die wir durchlebt haben, um das Ganze auf den Weg zu bekommen. Es war ein sehr kompliziertes Verfahren mit ganz, ganz vielen Seiten – 700 Seiten, glaube ich, alleine an Unterlagen vom Rat. Also es war kompliziert. Auslöser war – das hat eben meine Kollegin McGuinness schon gesagt und meine andere Kollegin hat es auch erwähnt – der Skandal um die Brustimplantate. Es ging jetzt um Patientensicherheit. Darum finde ich es an sich schade, dass die Besuchertribünen noch so leer sind. Denn es wäre schön, wenn ganz viele Menschen hier sehen würden, was wir in Europa doch Gutes tun, um die Patientensicherheit zu gewährleisten.</p>
<p class="contents">Es war von vornherein klar, als wir fertig waren mit den sehr schwierigen Verhandlungen, dass die Kommission jetzt am Zuge ist und ganz viel damit zu tun hat, überhaupt die Grundlagen für die Umsetzung dieser Verordnung zu schaffen.</p>
<p class="contents">Worum geht es? Wir alle wissen das hier, aber es geht eben bei den Medizinprodukten um alle möglichen Dinge, vom Heftpflaster bis zum Skalpell, es geht um den OP-Tisch, das Krankenhausbett, die künstliche Hüfte und das Kniegelenk genauso wie den Herzschrittmacher. Und all dies wird halt in der EU dezentral zertifiziert über die sogenannten „benannten Stellen“. In Deutschland ist das – was viele verwundert – sogar der TÜV, der eigentlich für Straßenverkehr zuständig ist, aber halt auch diese Zertifizierungen vornimmt.</p>
<p class="contents">2013 hatten wir 87 benannte Stellen in der EU, 2018 nur noch 59. Das waren also weniger statt mehr, und sieben davon sind halt im Vereinigten Königreich. Deswegen macht uns das durchaus sehr große Sorgen. Diese benannten Stellen nehmen ja eine ganz wichtige Rolle ein. Sie müssen Medizinprodukte zertifizieren. 30 bis 45 % der Medizinprodukte am Markt werden dort zertifiziert, und aufgrund von Spezialisierung kann das sogar noch erheblich höher sein. Im Orthopädiebereich, bei Hüft- oder Kniegelenken, sind es sogar 70 %, die dort zertifiziert werden, also wirklich noch ein erheblich größerer Anteil. Wir brauchen ja vieles davon Und durch die sinkende Zahl der benannten Stellen und auch angesichts der steigenden Zahl der Medizinprodukte in der EU stoßen die existierenden benannten Stellen bereits heute an ihre Kapazitätsgrenzen – ich sage es nochmal: Es sind weniger geworden.</p>
<p class="contents">Außerdem kommen neue Probleme dazu. Da nenne ich jetzt mal vier Punkte. Das eine: Es gibt wirklich Herausforderungen durch den Brexit, denn mit dem Brexit – wenn er denn kommt, ich hoffe immer noch, er kommt nicht – fallen im März 2019 eben einige Stellen weg – sieben, ich habe es schon gesagt. Und dann ist damit zu rechnen, dass der Andrang auf die in den anderen Mitgliedstaaten liegenden benannten Stellen wesentlich größer wird. Das ist natürlich etwas, was dann deutlich Kapazitätsgrenzen aufweist. Außerdem würden die im Vereinigten Königreich ausgestellten Zertifikate ihre Gültigkeit verlieren – da gab es mal eine Notiz der Kommission –, und die Geräte müssten dann entweder in den anderen 27 Mitgliedstaaten neu zertifiziert werden, bei einer der ohnehin schon überlasteten Stellen, oder sie müssen eben re-zertifiziert werden, oder es müsste eine Stelle aus dem Vereinigten Königreich in die EU verlegt werden, was mit Sicherheit bis März 2019 kaum durchführbar ist.</p>
<p class="contents">Dann kommt als dritter Punkt dazu, dass alle im Markt befindlichen Medizinprodukte bis Mai 2020 nach der neu geltenden Verordnung zertifiziert sein müssen. Der Prozess der Benennung der benannten Stellen, der Audit, gestaltet sich aus unserer Sicht eben doch nicht schnell genug. Frau Kommissarin, Sie sagten, die Kommission ist voll im Zeitplan. Wir haben die Befürchtung, dass es vielleicht doch nicht ganz so sein könnte. Denn die Hersteller können ja erst dann mit der Zertifizierung ihrer Medizinprodukte beginnen, wenn die benannten Stellen nach der neuen Medizinprodukteverordnung designiert sind. Derzeit gibt es noch keine einzige benannte Stelle, die wirklich designiert worden ist.</p>
<p class="contents">Vierter Punkt: Zusätzlich wird mit dem Anwendungsdatum der neuen Medizinprodukteverordnung im Mai 2020 eine höhere Arbeitsbelastung der benannten Stellen einhergehen, da mehr Medizinprodukte – Skalpell, OP-Lampe und so weiter – als bisher ein Zertifikat benötigen, und andererseits eine Flut von Neuzertifizierungen zu erwarten ist. Es ist absehbar, dass mit dem Anwendungsdatum der Verordnung nicht alle Produkte, die derzeit verwendet werden, ein Zertifikat haben werden, und damit wären sie nicht einsetzbar, und die Patientenversorgung wäre tatsächlich in Gefahr. Damit laufen wir auch Gefahr, dass die Patientenversorgung nach Mai 2020 wirklich schwierig werden kann und dass wir das nicht mehr gewährleisten können. Hüftgelenke mit einem Zertifikat aus dem Vereinigten Königreich könnten zum Beispiel vielleicht nicht rechtzeitig für die EU 27 nach dem März 2019 zertifiziert sein, OP-Grundausstattung wie ein Skalpell oder eine OP-Lampe, die derzeit kein Zertifikat haben und eben ab Mai 2020 eines benötigen, könnten dann aufgrund mangelnder Kapazitäten vielleicht noch nicht zertifiziert sein und damit nicht zur Verfügung stehen. Und darum ist es so – ich habe gehört, Frau Kommissarin, was Sie gesagt haben. Aber glauben Sie nicht vielleicht wirklich – was auch meine Kollegin Borzan gerade gesagt hat –, dass es vielleicht doch schlau wäre, das Anwendungsdatum um ein oder zwei Jahre zu verlängern, damit man auf der ganz sicheren Seite ist und keine Engpässe in der Patientenversorgung riskiert?</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-016-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23699.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:19:52&amp;playerEndTime=20181025-09:25:25" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kateřina Konečná, </span></span>  <span class="italic">za skupinu GUE/NGL</span><span class="bold">.</span> – Paní předsedající, vážené kolegyně, vážení kolegové, implementace nařízení o zdravotnických prostředcích a in vitro zdravotnických prostředcích má mnoho souvislostí. Jak na straně výrobců, oznámených subjektů i pacientů je ovšem bohužel nyní více otázek než odpovědí a já musím uznat, že mnohé jejich obavy jsou zcela na místě. Již nyní je jasné, že s sebou nová legislativa přináší nežádoucí snižování počtu oznámených subjektů. To bude znamenat zbrzdění vstupu nových technologií i omezení dostupnosti starších prostředků. Např. v České republice, ze které pocházím, nám zbyly již jen dva oznámené subjekty a nedávno jich bylo ještě pět. Takové Rakousko již nemá ani jeden. Zbylé oznámené subjekty se již teď topí v práci a v žádostech a nestačí je vyřizovat, natožpak brát nové klienty ze zemí, kde již neexistuje žádný oznámený subjekt, čímž začínají být výrobci zdravotnických prostředků z těchto zemí pomalu vytlačováni z trhu. Z implementovaných a delegovaných aktů byl přijat, pokud vím, jen jeden, a i kdyby mi nějaký náhodou utekl, tak v této fázi jde o absolutně skandální bilanci. Zvláště za situace, kdy první nařízení plně vstoupí v účinnosti již v květnu 2020.</p>
<p class="contents">Než je možné provést oznámení do databáze NANDO, je nezbytně nutné zveřejnit na webu notifikační proceduru jednotlivých členských států. Před létem tam nebyla zveřejněna ani jedna notifikační procedura. Celkově na evropské úrovni dochází ke zpomalení a přechodné období u nařízení o zdravotnických prostředcích se přestává zdát jako dostatečné. Pokud se situaci nepovede vyřešit, pocítí výsledky pacienti. A to vůbec ani nezmiňuji, že až 40 % současných evropských certifikátů je z Británie. Tamní notifikované osoby však EU dle vysvětlujících dokumentů z Evropské komise s brexitem zcela ztratí. Navíc se odhaduje, že kolem poloviny zplnomocněných zástupců v odvětví zdravotnických prostředků sídlí v Británii. Některé subjekty již oznámily, že přesunou svá sídla do EU, ale určitě to neudělají všechny. Vstup prostředků na trh se z těchto důvodů velmi zpomalí. Mám proto tři dílčí otázky:</p>
<p class="contents">Za prvé, nově zpřísněné požadavky nařízení o zdravotnických prostředcích jsou postaveny na <span class="italic">evidence based</span> principu a důkazech založených na vědecky správně interpretovaných faktech. Ráda bych proto slyšela od Evropské komise nějaké důkazy pro její současný klid. Domnívají se zástupci Evropské komise, že implementace obou nařízení probíhá úspěšně podle časového harmonogramu a na trhu tedy nedojde k zásadním problémům po květnu 2020? Může Evropská komise garantovat, že nedojde k přechodnému vyřazení většího množství zdravotnických prostředků z trhu v důsledku nedostatku oznámených subjektů a jejich kapacit? Má Evropská komise k tomuto závěru vypracované nějaké konkrétní studie či hlubší <span class="italic">assessments</span> a jaké jsou z nich konkrétní poznatky? Jakými statistikami může Evropská komise tyto závěry podpořit? Jsou tyto statistiky veřejně dostupné?</p>
<p class="contents">Za druhé, úzkým hrdlem pro vstup zdravotnických prostředků na trh je v současnosti kapacita oznámených subjektů. Je pravda to, co tady často slyšíme v kuloárech, že Evropská komise preferuje odstranění všech menších oznámených subjektů s cílem dosažení redukce jejich počtu na cca 10 a zaměření se na několik málo velkých? Můžete doložit budoucí kapacitní analýzy? Před létem bylo 59 oznámených subjektů podle staré legislativy, kolik je podle Evropské komise tedy optimální a dostatečný počet pro zajištění fungování trhu?</p>
<p class="contents">Za třetí, jedním ze základních stavebních kamenů nařízení o zdravotnických prostředcích jsou harmonizované normy a společné specifikace. Pokud jde o normy a jejich harmonizaci na nařízení o zdravotnických prostředcích, je již nyní plánováno značné zpoždění. Některé důležité normy, jako např. posouzení biokompatibility, budou harmonizovány až v květnu 2024, tedy 4 roky po účinnosti prvního nařízení. Proč k tomu došlo a jaký je plán k řešení tohoto zpoždění?</p>
<p class="contents">Pevně věřím, paní komisařko, že dnes máte jedinečnou příležitost vyvrátit nejen mé pochybnosti o Vaší nečinnosti, respektive o nečinnosti Komise, ale především pochybnosti lidí, kteří tento bod sledují, států, které se obávají o to, že nebudou mít dostatek kvalitních a registrovaných zdravotnických prostředků, a pacientů, kteří si zoufale stěžují na to, že neví, jak to dítě legislativy, kterou zde máme, bude fungovat po roce 2020.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-017-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96952.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:24:44&amp;playerEndTime=20181025-09:25:13" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">La Présidente. – </span></span>  Madame Konečná et Madame Borzan, voulez-vous mettre vos écouteurs s’il-vous-plaît? Madame Borzan, vous avez vos écouteurs?</p>
<p class="contents">Il semblerait qu’il y ait eu un petit problème de traduction signalé par Mme Borzan et qui aurait fait réagir Mme Konečná donc, a titre exceptionnel, pour être sûr qu’il n’y a pas d’ambigüité sur vos propos Madame, veuillez, Mme Borzan, prendre la parole 30 secondes sur ce problème d’interprétation que vous auriez repéré.</p>
<p class="contents">Vous avez 30 secondes Madame.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-018-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112748.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:25:12&amp;playerEndTime=20181025-09:25:46" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Biljana Borzan (S&amp;D).</span></span>   – Poštovana predsjedavajuća, ja sam na kraju svoga izlaganja rekla da nisam sklona ponovnom otvaranju regulative. Nažalost, prevedeno je obrnuto. Kasnije se kolegica Meissner osvrnula da podržava mene. Međutim, tu imamo potpuno suprotna stajališta.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-019-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96952.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:25:38&amp;playerEndTime=20181025-09:25:52" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">La Présidente. – </span></span>  Parfait, je pense que cela ne s’adressait donc pas à Mme Konečnà mais à Mme Meissner, mais là je pense que les choses sont claires, en tout cas, et sans ambiguïté.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-020-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124765.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:25:53&amp;playerEndTime=20181025-09:28:10" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Joëlle Mélin, </span></span>  <span class="italic">au nom du groupe ENF</span><span class="bold">.</span> – Madame la Présidente, avec cette question orale sur la mise en œuvre des deux règlements sur les dispositifs médicaux et de diagnostic in vitro, nous parlons d’un marché potentiel de 110 milliards d’euros.</p>
<p class="contents">Compte tenu de la gravité du sujet, à savoir la santé des Européens, aussi bien sur le versant préventif que curatif, cette considération financière ne devrait pas être au premier plan.</p>
<p class="contents">Et pourtant, le scandale des prothèses mammaires de l’entreprise PIP, en France, a révélé combien le rôle des organismes notifiés, c’est-à-dire ceux qui homologuent les dispositifs médicaux, est fondamental et gravissime lorsque ceux-ci sont défaillants.</p>
<p class="contents">Une réforme s’imposait donc; de nouveaux règlements ont été votées qui, 18 mois après, ne règlent rien, car compte tenu de la lourdeur de la machine européenne, comme d’habitude, les conséquences se font voir, à savoir que seuls 30 % des organismes notifiés existants auraient redemandé leur validation. Le fait est aussi que beaucoup étaient britanniques.</p>
<p class="contents">Les déficiences de ces organismes sont très inquiétantes, aussi bien pour ce qui est de leur nombre que de la qualité des experts qui les composent, mais aussi de la durée des processus d’homologation.</p>
<p class="contents">Il en va de la santé de tous les Européens, car les dispositifs médicaux vont du sparadrap à la circulation extracorporelle, des lunettes aux prothèses de hanche; quant aux dispositifs de diagnostic, ils sont fondamentaux dans la pratique quotidienne, mais aussi pour la prévention à moyen et long terme.</p>
<p class="contents">Ce retard pris pèse aussi lourdement sur de nombreuses start-ups ou des grandes entreprises innovantes, particulièrement en France où l’autocontrôle se développe très rapidement.</p>
<p class="contents">Madame la Commissaire, vous nous dites que tout se met en place, mais force est de constater qu’un retard sérieux s’installe. Ce qui, pour le moins, aggrave encore le climat de méfiance après les très nombreux scandales déjà anciens.</p>
<p class="contents">Doit-on craindre un monopole de quelques géants de la certification?</p>
<p class="contents">Il y a urgence, Madame, faute de quoi les États membres reprendront légitimement la main pour protéger la santé de leurs citoyens, vous le comprendrez. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-021-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28223.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:28:20&amp;playerEndTime=20181025-09:30:40" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Andreas Schwab, </span></span>  <span class="italic">im Namen der PPE-Fraktion</span><span class="bold">.</span> – Frau Präsidentin, liebe Kolleginnen und Kollegen! Zunächst einmal muss ich sagen, dass ich verspätet gekommen bin, weil die Notarztwägen hier in Straßburg eine Streikaktion durchführen. Das hängt im weiteren Sinn ja sicherlich auch mit der Medizinprodukteverordnung zusammen.</p>
<p class="contents">Aber ganz im Ernst: Ich glaube, dass das, was an Argumenten bereits vorgetragen wurde, Frau Kommissarin, von wirklich großer Bedeutung ist, denn es finden sich ja momentan in der Europäischen Union rund 500 000 Medizinprodukte auf dem Markt. Diese Produkte müssen den neuen Anforderungen für Patientensicherheit genügen. Aber sie müssen in jedem Falle für die Menschen, die darauf angewiesen sind, diese Produkte unmittelbar zu bekommen – auch jetzt und in den kommenden Monaten –, in hoher Sicherheit zur Verfügung stehen.</p>
<p class="contents">Deswegen ist die Tatsache, dass wir bei den genannten Stellen diese Verzögerung haben, für die Patientinnen und Patienten in der Europäischen Union, die heute auf ein Produkt warten, schlicht und ergreifend ein großes Problem. Vor diesem Hintergrund möchte ich Sie einfach ausdrücklich darum bitten, dass wir alles dafür tun, die Zahl der benannten Stellen in einem Rahmen zu vergrößern, der es uns erlaubt, möglichst schnell die neue Medizinprodukteverordnung anzuwenden. Frau Kollegin McGuinness, die ja an diesem Dossier erheblich mitgearbeitet hat, hat schon darauf hingewiesen.</p>
<p class="contents">Es fehlen immer noch die Durchführungsrechtsakte, die verbindlich für die Zertifizierung sind. Ich glaube, dass Sie alle verstehen, dass die Unternehmen, die diese Produkte herstellen, sich natürlich auf die neuen Vorschriften nur einstellen können, wenn sie mit einer entsprechenden Vorlaufzeit wissen, welche Anforderungen sie im Einzelnen zu erfüllen haben.</p>
<p class="contents">Jetzt ist mir natürlich klar, dass es durchaus auch so sein kann, dass die Mitgliedstaaten hier eine Mitverantwortung tragen. Das ist keine Frage. Aber es hilft am Ende den Unternehmen wenig, wenn wir als Politiker die Schuld zwischen den staatlichen Ebenen hin- und herschieben. Die Unternehmen brauchen Rechtssicherheit und sie wollen, nach meinem Kenntnisstand, auch die Vorgaben der neuen Medizinprodukteverordnung umsetzen.</p>
<p class="contents">Deswegen sollte die heutige Aussprache unbedingt dazu genutzt werden, mit der Europäischen Kommission nach Lösungen zu suchen, dass die Unternehmen, die in Europa für die Patientensicherheit – aber eben auch für die Patientengesundheit – lebenswichtige Produkte im Einzelnen herstellen, die Möglichkeit haben, das auch in den kommenden Monaten rechtssicher zu tun. Darum bitte ich alle Kollegen und insbesondere die Europäische Kommission. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-022-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/192298.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:30:47&amp;playerEndTime=20181025-09:32:24" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dobromir Sośnierz (NI).</span></span>   – Pani Przewodnicząca! To zapytanie to jest prawdziwy wehikuł czasu. Jak czytam te zatroskane pytania: jak to będzie, czy na pewno łańcuch dostaw artykułów medycznych przetrwa naszą kolejną regulację, to przypominają mi się jeszcze zebrania naszej partii komunistycznej, które pamiętam z dzieciństwa, jak to co roku mędrcy komunistyczni spotykali się, żeby zastanawiać się, jak w tym roku sprawnie przeprowadzić zbiory. A potem i tak wszystko wywalało się, dlatego że brakowało sznurka do snopowiązałki. Gdzie indziej, w innych krajach, jeszcze wtedy na normalnym w miarę Zachodzie, nie było mędrców obradujących nad sznurem do snopowiązałki i sznur do snopowiązałki zawsze był. A u nas nie było.</p>
<p class="contents">I teraz również, mieliśmy dostatek artykułów medycznych, nikomu ich nie brakowało, no to Unia Europejska postanowiła to uregulować i teraz będziemy się martwić, czy się z tym wszystkim wyrobimy, czy nam się wszystko nie pozawala, bo mamy trzy dyrekcje, które ze sobą nie wiadomo jak będą współpracować, więc może powołajmy czwartą, która będzie koordynować ich działanie, a potem piątą, która zajmie się ich unifikacją. Taką właśnie drogą idzie Unia Europejska. Tak że myślę, że nasz tekturowy Altiero Spinelli w holu budynku w Brukseli pręży się z dumy, jak widzi, w jakim kierunku poszła ta organizacja, która była założona jako narzędzie do wolnego handlu i znoszenia regulacji, a stała się naprawdę kolejną Międzynarodówką Komunistyczną.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-023-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124704.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:32:26&amp;playerEndTime=20181025-09:35:49" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Stanislav Polčák (PPE).</span></span>   – Paní předsedající, já pouze na konto toho, co jsme slyšeli, musím říci, že i moje maminka a rodiče velmi vzpomínají na dobu právě komunistickou, o které hovořil pan Sośnierz, kdy chyběly základní zdravotnické prostředky v Československu a dost pochybuji, že by nechyběly v Polsku, takže to je trochu vyjádření v souvislosti s tím, co řekl kolega Sośnierz.</p>
<p class="contents">Nicméně, nové předpisy o zdravotnických prostředcích a diagnostických zdravotnických prostředcích in vitro schválené v roce 2016 pomáhají zajistit, aby všechny zdravotnické prostředky byly bezpečné a dobře fungovaly. Týká se to kontaktních čoček, rentgenů, prsních implantátů, umělých kloubů atd. Za tímto účelem nová pravidla zlepšují dohled nad trhem a vysledovatelnost a zavádí přísnější kontroly zdravotnických prostředků. Jsem přesvědčen, ať už se jedná o zdravotnické prostředky, automobily nebo o jiné výrobky, je třeba zajistit skutečně dohled v zájmu našich občanů. A od těchto nových pravidel bychom si měli slibovat větší transparentnost, právní jistotu pro výrobce a dovozce, posílení mezinárodní konkurenceschopnosti a také nové inovace v tomto strategickém odvětví. </p>
<p class="contents">Nicméně, již v průběhu tříletého přechodného období, které končí v květnu 2020, se ukazuje, že uplatňování nařízení o zdravotnických prostředcích a diagnostických zdravotnických prostředcích in vitro se potýká s problémy a některé prvky nového systému se skutečně nedaří optimálně připravit. Bylo o tom zde již mnoho řečeno, týká se to např. problematického spuštění zmíněné databáze Eudamed, která by měla integrovat různé elektronické systémy. Řádné fungování právě této databáze je přitom velmi důležité, protože jejím cílem je zlepšit přístup k informacím pro veřejnost a také zdravotnické pracovníky, aby se např. zabránilo vícenásobným požadavkům na ohlašování a aby se také zefektivnil nebo usnadnil tok informací mezi hospodářskými subjekty.</p>
<p class="contents">Proto se chci Komise zeptat, vážená paní komisařko, zda Komise skutečně je přesvědčena, že tato databáze bude fungovat, zda k tomu vytvořila potřebné podmínky a zda tato databáze bude sloužit svému účelu, který jsem předestřel. To je zejména pro zdravotnické pracovníky, ale samozřejmě i pro občany, kteří musí vědět, jestli např. jejich konkrétní implantát bude slučitelný s průchodem skenerem na letišti. </p>
<p class="contents">Dalším problémem hodným zmínky je nedostatečný počet oznámených subjektů, které odpovídají za certifikaci zdravotnických prostředků. Komise by proto měla tuto situaci neprodleně začít řešit, aby se předešlo narušení dodávek důležitých zdravotnických prostředků na trh. Od Komise také očekávám, že zlepší koordinaci mezi třemi dotčenými generálními ředitelstvími, aby se novému systému dostalo potřebné administrativní podpory.</p>
<p class="contents"><span class="italic">(Řečník odmítl otázku, kterou chtěl zvednutím modré karty položit Dobromir Sośnierz.)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-024-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124739.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:35:48&amp;playerEndTime=20181025-09:38:31" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Carlos Zorrinho (S&amp;D).</span></span>   – Senhora Presidente, a regulamentação do uso dos dispositivos médicos e dispositivos médicos de diagnóstico <span class="italic">in vitro</span>, baseado na definição de regras de conceção e fabrico, ensaios clínicos, autorização, comercialização e vigilância pós-comercialização, veio a revelar-se incapaz de impedir a circulação no nosso mercado de dispositivos de baixa qualidade, com graves consequências para os utilizadores, deixando a descoberto graves lacunas no sistema legislativo.</p>
<p class="contents">É, por isso, importante salientar o trabalho realizado no Parlamento Europeu sobre esta matéria, que deu origem a várias propostas para melhorar o funcionamento, a fiabilidade e a segurança destes dispositivos. É certo que alguns Estados—Membros têm reagido menos entusiasticamente à definição de quadros normativos partilhados porque, efetivamente, existe uma reserva legislativa em matéria de saúde.</p>
<p class="contents">No entanto, o trabalho empenhado da Comissão Europeia e do Parlamento Europeu em diálogo, que é sempre fundamental com os Estados—Membros, tem vindo a tornar possível dar passos significativos na cooperação em domínios de promoção da qualidade da saúde, que têm, como é este o caso, uma dimensão claramente transfronteiriça.</p>
<p class="contents">O reforço da regulação dos dispositivos médicos de diagnóstico <span class="italic">in vitro</span> para garantir testes tão importantes como os testes de gravidez ou os exames de sangue é preciso, tem de ser preciso e confiável e configura bem um exemplo onde essa cooperação entre os Estados—Membros é importante e tem de ser ainda mais reforçada.</p>
<p class="contents">O quadro normativo que entrou em vigor em 25 de maio de 2017, com prazo de transição de 3 e 5 anos respetivamente, garante uma boa qualidade desses dispositivos e a consequente proteção dos doentes. Contudo, neste período de transposição, têm sido identificadas dificuldades de implementação do sistema, designadamente na operacionalização da colaboração entre os Estados—Membros e as instâncias europeias.</p>
<p class="contents">A questão da certificação dos dispositivos médicos no Reino Unido é também relevante, já que, após a sua saída da União Europeia, todos os organismos notificados sedeados neste país vão deixar de poder realizar avaliações de conformidade em consonância com a legislação europeia.</p>
<p class="contents">A promoção da saúde é legalmente uma competência intergovernamental, mas o superior interesse dos cidadãos exige parcerias e respostas concertadas. É por isso que, neste contexto, as questões que foram colocadas à Comissão são de enorme oportunidade e as respostas merecem toda a nossa atenção e todo o nosso acompanhamento. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-025-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28115.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:38:33&amp;playerEndTime=20181025-09:41:41" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mairead McGuinness (PPE).</span></span>   – Madam President, the great thing about technical debates is that we are few in number in the debate so we get extra time to respond and I think it’s hugely important. I think it’s also true to say that, if there was a scandal tomorrow on the medical devices industry, this Chamber would be full, so we need to understand that. We’ve lived through a really bad experience and the reputable industry suffered, while the rogues perhaps were not penalised sufficiently. So let me just put that down as a marker. </p>
<p class="contents">I want to respond in particular to the answers you’ve given us, Commissioner. I applaud your optimism. I’m quoting my notes here – we’re on track, there’s no delay, there are no alarm bells – and, as Commissioner, you need to show that confidence. But that is not what we are hearing. I’m not raising an alarm bell, but I am raising concerns that I am hearing from regulators, from patient groups and from industry about whether we can implement in full and on time. Like others. I’m not calling for any delays in implementation. I think that would be a really bad signal to our citizens because it took us a long time to get to this place. But I want to make sure that we will actually do that: implement in full and on time. So, I do need you to come back to some of those questions and give me more assurances that we are on track and that there are no delays.</p>
<p class="contents">Some colleagues raised the issue of the reduction in the numbers of notified bodies. These are the regulators, if you like, that work with industry to make sure products are safe. Let’s remind ourselves of the facts: Before we started on this process of updating our legislation, there were 80 notified bodies across the European Union. When we sent in the auditors, we found that many were not fit for purpose and that there are only 59 of that 80 still operating. That should be an alarm bell. We hope that those 59 are all fit for purpose, that they will apply for re-designation and that it happens on time. </p>
<p class="contents">Commissioner, I want to speak about Brexit because I think you need to give us more detail. For example, many would believe that, because we will hopefully have a withdrawal agreement, there will be a transition or implementation period and that nothing will change around the medical devices sector until the end of that period. But, as I heard from you, that is not the case, so please clarify when the change comes. Is it at the end of March or at the end of the transition?</p>
<p class="contents">The second question – and perhaps the more pertinent one – is that the UK is a major player in this industry and also has many notified bodies. More detail please on what those notified bodies, that are located in the United Kingdom, are doing so that they can continue their work because I fear, if they left the stage, then we do have an alarm bell and we will be ringing it. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-026-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/185619.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:41:47&amp;playerEndTime=20181025-09:44:25" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tiemo Wölken (S&amp;D).</span></span>   – Frau Präsidentin! Die beiden neuen Verordnungen, wie es hier schon mehrmals im Raum gesagt wurde, sollen den Zugang von Patientinnen und Patienten in der Europäischen Union zu sicheren und wirksamen Medizinprodukten sicherstellen.</p>
<p class="contents">An diesem Ziel halten wir als Haus auch definitiv fest. Wie wichtig das ist, haben nicht zuletzt die Skandale der fehlerhaften Brustimplantate oder Hüftgelenke gezeigt. Nur wir auf europäischer Ebene können die gemeinsamen Standards setzen, weil Medizinprodukte eben auch im europäischen Binnenmarkt gehandelt werden und Grenzen überqueren. Das zeigt ja auch das Beispiel Brexit sehr deutlich,</p>
<p class="contents">Unsere Priorität war bei der gesamten Gesetzgebung, die sich ja leider sehr lange gezogen hat, immer die Patientensicherheit. Dieser Patientensicherheit tragen die beiden Texte Rechnung. Sie erhöhen die Anforderungen an die Hersteller medizinischer Produkte oder auch an Überwachungsvereine wie den TÜV oder die Dekra. Als Parlament haben wir in der neuen Verordnung unter anderem dafür gesorgt, dass die Hersteller medizinischer Produkte künftig eine angemessene Versicherung brauchen, sodass im Schadensfall die Patientinnen und Patienten zumindest finanziell abgesichert sind.</p>
<p class="contents">Aber es kann doch nicht sein, dass wir jetzt kurz vor dem Umsetzungsdatum feststellen müssen, dass wichtige Durchführungsrechtsakte noch nicht auf dem Tisch liegen und wichtige Maßnahmen, die zur Verbesserung der Patientensicherheit führen, dann tatsächlich nicht umgesetzt sind. Ich finde, es darf nicht sein, dass kurz vor Inkrafttreten der Verordnung auf einmal die erforderlichen Elemente des Systems nicht vorbereitet werden.</p>
<p class="contents">Insbesondere gibt es – und das haben meine Kolleginnen und Kollegen ja auch schon sehr richtig benannt – das Problem bei der fristgerechten Benennung der <span class="italic">notified bodies, </span>der benannten Stellen. Das ist das Kernelement der Verordnung. Für mich muss deswegen ganz deutlich hier gesagt werden, dass das definitiv umgesetzt werden muss. Es kann nicht die Lösung sein, dass das Anwendungsdatum dieser Verordnung, die wir so lange durchgefochten haben – auch mit dem Rat –, verschoben wird.</p>
<p class="contents">Es muss sichergestellt sein, dass im Mai 2020 der Anwendungszeitraum beginnt. Die Antwort der Kommissarin auf die <span class="italic">notified bodies </span>reicht mir nicht. Ich sehe nicht, dass die Patientensicherheit in der Europäischen Union wirklich gewährleistet ist, und würde mich daher noch mal über eine Präzisierung freuen und gehe, genauso wie die Kollegin McGuinness, noch mal mit der Bitte hier in die Runde, deutlich zu machen, was der Brexit bedeutet. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-027-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125041.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:44:29&amp;playerEndTime=20181025-09:46:49" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Soledad Cabezón Ruiz (S&amp;D).</span></span>   – Señora presidenta, ya se ha dicho aquí; recordamos todos los escándalos que hubo con las prótesis mamarias: cientos de miles de personas afectadas; recordamos todos el escándalo con las prótesis de cadera de la empresa Traiber: desde 2014, en el caso de España, setenta y cuatro personas reoperadas, y a una de ella le costó incluso la vida.</p>
<p class="contents">Por lo tanto, no estamos hablando de un tema baladí. Se trata de la seguridad de los pacientes. Yo puedo entender que la Comisión se enfrenta a un nuevo reto que necesita personal cualificado, que también nos encontramos ante la situación del <span class="italic">Brexit </span>y que, efectivamente, gran parte de estas evaluaciones y de estos expertos procedían del Reino Unido, pero, realmente, eso no puede ser una excusa para una moratoria ni para retrasar la implementación de un Reglamento que ya ha tardado mucho y que ha tenido moratoria suficiente.</p>
<p class="contents"> Por lo tanto, pido que se tomen las medidas necesarias para que se implemente. Estamos hablando —como digo— de la seguridad de los pacientes. Un Reglamento, además, que parte con la seguridad como objetivo pero que, quizá, adolece de la falta de ambición necesaria. Sería necesario, incluso, que contemplase la eficacia, porque lo ideal sería que tuviésemos un sistema de autorización centralizado en la Unión Europea para este tipo de dispositivo, que asegurase la seguridad y la eficacia. </p>
<p class="contents">Hoy hablamos de seguridad como primer paso; tendremos que seguir hablando de eficacia. Pero le pido a la Comisión que se ponga las pilas porque, efectivamente, es uno de los grandes retos a los que se enfrentan los sistemas nacionales de salud y los pacientes hoy en día. Por lo tanto, le animo a que no demore más la introducción y la implementación de este de este tipo de reglamentación.</p>
<p class="contents">Y, por último, una cuestión en concreto. ¿Es todo un problema burocrático o también hay presiones por parte de algún sector interesado o por algún sector que considera que aún no está preparado para que esto se pueda implementar? Me gustaría saberlo, porque realmente creo que es una oportunidad incluso para la competitividad de la Unión Europea en términos de calidad. Soy consciente de que hay cierta resistencia y me gustaría saber si solamente se trata de un problema burocrático. </p>
<p class="contents"><span class="italic">(La oradora acepta responder a una pregunta formulada con arreglo al procedimiento de la «tarjeta azul» (artículo 162, apartado 8, del Reglamento interno)).</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-028-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96870.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:47:05&amp;playerEndTime=20181025-09:47:47" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gesine Meissner (ALDE), </span></span>  <span class="italic">Frage nach dem Verfahren der „blauen Karte“</span><span class="bold">.</span> – Ja, ich bin ja die Einzige, die bis jetzt gesagt hat: Notfalls müssen wir eben eine Verlängerung der Fristen nehmen. Das ist natürlich überhaupt nicht das, was ich gerne möchte. Klar wäre es am besten, wenn wir bis 2020 die Implementierung umgesetzt haben. Aber liebe Kollegin Soledad, glauben Sie nicht auch, dass es vielleicht schlauer wäre, über eine Verlängerung der Frist nachzudenken, wenn man dann wirklich sehen sollte, dass es nicht funktioniert, rechtzeitig fertig zu sein?</p>
<p class="contents">Wir haben ja alle die Befürchtung, es könnte sein, dass die Kommission nicht rechtzeitig mit der Designierung der benannten Stellen fertig wird. Das ist meine Sorge. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-029-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125041.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:47:46&amp;playerEndTime=20181025-09:48:39" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Soledad Cabezón Ruiz (S&amp;D), </span></span>  <span class="italic">respuesta de «tarjeta azul»</span><span class="bold">.</span> – Soy consciente de que todos queremos que esta implementación se haga lo antes posible, pero yo quería preguntar a la Comisión si es solo, efectivamente, un problema burocrático, de medios, de personal, de cualificación. Si es así, tenemos que estudiarlo, aunque eso no implica que no tengamos que pedirle que, por favor, acelere y se comprometa con un tema de seguridad como este. Pero también he querido hacer ver o preguntar si, efectivamente, puede haber algún tipo de inseguridad o duda de que esto no pueda ir, digamos, todo lo rápido posible porque hay algún sector que considera que no está preparado para ello.</p>
<p class="contents">Creo que, si eso es así, tenemos que evitarlo, porque el Reglamento es más necesario que nunca. Yo creo que el sector sí está preparado y Europa necesita que entre a formar parte de este Reglamento.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-030-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96743.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:48:42&amp;playerEndTime=20181025-09:52:03" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Michèle Rivasi (Verts/ALE).</span></span>   – Madame la Présidente, pour moi ce sujet est très important et – j’anticipe – je pense qu’il va y avoir un scandale sanitaire sur ces dispositifs médicaux. Pourquoi? Parce que lorsque nous avons travaillé sur ce règlement, nous voulions faire un organisme centralisé, comme ce qui existe aux États-Unis, mais les libéraux et les conservateurs n’ont pas voulu en disant: on va faire confiance aux organismes de certification. Alors, j’ai regardé les organismes de certification et je sors un numéro de référence où il y a un extrait d’un rapport de synthèse de la DG «Santé et sécurité alimentaire». Que dit ce rapport interne? Que des évaluations conjointes – vous savez qu’il y avait 78 organismes de certification et maintenant on pense qu’il n’y en aura plus que 53 – montrent qu’il y a des problèmes récurrents et persistants en ce qui concerne la façon de travailler des organismes notifiés et leur capacité à satisfaire aux conditions de désignation prévues par les directives: manque d’indépendance, impartialité du personnel des organismes notifiés, insuffisance des éléments justifiant la qualification du personnel et leur affectation à des fonctions spécifiques d’évaluation de la conformité et une réalisation loin d’être optimale des évaluations de conformité portant sur les dispositifs médicaux. </p>
<p class="contents">Alors, c’est votre rapport interne qui montre que les organismes de certification sont des organismes privés et à partir du moment où ils sont privés, ils sont juges et parties, et en même temps ils n’ont pas la qualification au niveau des experts. C’est vous qui le dites! Alors lorsqu’on va avoir des implants – vous voyez, des choses qui sont à l’intérieur du corps – et s’il n’y a pas de bons épidémiologistes, s’il n’y a pas de personnel qualifié pour évaluer les études cliniques, pour analyser l’impact des métaux au niveau, par exemple, des os et du sang – ce qui s’est passé pour les prothèses de hanche –, alors nous allons au-devant de scandales sanitaires. </p>
<p class="contents">Pour ne citer qu’un exemple parmi d’autres: lors du scandale des prothèses PIP en France, l’organisme allemand TÜV est allé les contrôler et ils n’ont pas vu que les éléments constitutifs de ces prothèses n’étaient pas conformes. En ce qui concerne les prothèses de hanches ASR, elles ont été commercialisées par Johnson &amp; Johnson de 2003 à 2010. 93 000 personnes dans le monde, dont plus d’une centaine en France, ont eu ces prothèses. Ce ne sont pas les organismes de notification qui ont signalé le problème: ce n’est que parce que les États-Unis les ont interdites, puis l’Australie, que la France a fini par les interdire aussi. Vous voyez bien que nous ne sommes pas à la hauteur des enjeux. Sur les pacemakers et le reste il y aura aussi des scandales parce que notre système ne fonctionne pas tel qu’il est.</p>
<p class="contents">On nous a dit: pas d’organisme centralisé, parce qu’il faut favoriser l’innovation. Mais l’innovation au détriment de la sécurité des patients, ce n’est pas acceptable. Il faut donc envisager un organisme centralisé sous l’égide de la Commission européenne qui analyse plus spécifiquement l’efficacité et la sécurité des dispositifs.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-031-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:51:51&amp;playerEndTime=20181025-09:52:10" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">Interventions à la demande</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-032-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124785.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:52:10&amp;playerEndTime=20181025-09:53:24" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria Grapini (S&amp;D).</span></span>   – Doamna președintă, doamna comisar, stimați colegi, dezbaterea de astăzi arată că avem încă multe de făcut în acest domeniu și trebuie să pornim de la siguranța și securitatea pacienților, așa cum s-a subliniat foarte mult aici. Au intrat în piață noi producători, avem companii care fac proteze, cabinete care fac implanturi însă rezultatele, doamna comisar, în multe state sunt negative. Sunt pacienți care rămân pe viață invalizi după intervenția cu anumite dispozitive. Și eu cred că aici trebuie să ne gândim nu neapărat să facem repede lucrul, ci să îl facem bine. Și mă bucur că au fost și alte asemenea voci aici.</p>
<p class="contents">Aș vrea să vă întreb dacă dumneavoastră considerați că acum, când suntem în faza de a implementa acest regulament într-un anumit termen, avem studii actualizate vizavi de efectul pe care îl au implanturile, efectul pe care îl au protezele, pentru că așa ați putea ajuta statele membre. Sănătatea este sub subsidiaritate, dar putem aici să avem, european, niște elemente care să ajute statele membre în implementarea regulamentului.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-033-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125069.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:53:27&amp;playerEndTime=20181025-09:54:39" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Νότης Μαριάς (ECR).</span></span>   – Κυρία Πρόεδρε, η τεχνολογία αξιοποιείται βεβαίως και στα θέματα της υγείας και πολύ σωστά γίνεται αυτό, διότι έτσι μπορούμε να έχουμε μία πρόοδο. Έχουμε, λοιπόν, πάρα πολλά ιατροτεχνολογικά προϊόντα. Έχουμε in vitro διαγνωστικά ιατροτεχνολογικά, άλλα προϊόντα, τα οποία, βεβαίως, δημιουργούν ένα κύκλο εργασιών μαζί με τις παρεμβάσεις στην υγεία εκατόν δέκα δισεκατομμύρια ευρώ. Είναι πάρα πολλά τα λεφτά, όπως λένε. Έχουμε, λοιπόν, προσθετικές, τις ακτίνες, τα τεστ αίματος, τεστ εγκυμοσύνης, τους βηματοδότες. Αντιλαμβάνεται κανείς ότι πρέπει να υπάρχουν προδιαγραφές και οι προδιαγραφές αυτές πρέπει να εγκρίνονται από πιστοποιημένους οργανισμούς, οι οποίοι πρέπει να έχουν ορισμένες προδιαγραφές επίσης. Να έχουν την αναγκαία τεχνολογία. Να μην υπάρχει σύγκρουση συμφερόντων. Να έχουνε την εμπειρογνωμοσύνη και, θα έλεγα, να έχουνε και ένα δημόσιο χαρακτήρα. Γι’ αυτό πιστεύω ότι σε μεγάλο βαθμό πρέπει να είναι δημόσιος χαρακτήρας των οργανισμών που πιστοποιούν και, αν έχουμε ιδιωτικούς φορείς, θα πρέπει να υπάρχει διασφάλιση για τη σύγκρουση συμφερόντων για να είμαστε βέβαιοι ότι γίνεται σωστά η δουλειά.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-034-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124963.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:54:46&amp;playerEndTime=20181025-09:56:04" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Julie Ward (S&amp;D).</span></span>   – Madam President, I would like to use this opportunity to pay tribute to the important work of Dame Glenis Willmott, who until a year ago was the leader of the British Labour delegation here in the European Parliament. Glenys knew her subject because she had worked in the health sector as a trade union representative. Her work on the safety of medical devices was promoted by the scandal of leaking breast-implants; an issue that seriously threatened the health of women, and I am proud that we have real experts in our political group working for the benefit of all Europeans, and I have to say that my colleague Mrs McGuinness is correct: Brexit threatens the future health of people in the UK and Ireland. It also threatens research: ground-breaking research is what makes medicines and health innovations possible – and outside of the EU, the UK is taking a retrograde step in terms of its position on the world stage. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-035-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:56:02&amp;playerEndTime=20181025-09:56:11" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">(Fin des interventions à la demande)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-036-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-09:56:07&amp;playerEndTime=20181025-10:00:55" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elżbieta Bieńkowska,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Madam President, I would to thank the honourable Members for all their remarks. First, many of you said that I am optimistic and calm. I would rather put it in other words: Iʼm realistic and confident. It does not mean that we are not monitoring proactively everything that is going on, that we are not watching the process. But for now, we are in the timeline, we are on track and in the timeline, and this is the most important thing.</p>
<p class="contents">I would also like to underline that with this regulation, European citizens – EU citizens – will receive the most reliable, the most innovative and the safest healthcare in the world. This is the aim of this legislation. This is why we doing this, for the safety of our citizens.</p>
<p class="contents">Let me refer to a few points that you raised. First, on the number of notified bodies. For now, we have 60 of them and 34 applications, so more than half have been received by the Commission. There have been no delays so far in the assessment of notified bodies that have been submitted to us. According to our data, the first notified bodies might be available even before the end of this year, so a few months in advance of the timeline.</p>
<p class="contents">As for the transition period for this directive (not Brexit), in order to smooth the transition, the two regulations foresee a specific exemption mechanism – of course under certain conditions, namely the extension of the validity of the old certificates and the exemption of certain devices from the new, more strict clinical investigation requirements. Those exemptions and those applications may end even in May 2024, so we have some exemptions in the regulation.</p>
<p class="contents">Brexit: an extremely important topic. You mentioned the transition period, but of course the transition period for Brexit is much more general and much broader than only the medical devices industry. It applies to all of the industrial sectors, and of course if any transition period for general transition periods is agreed, then it will also apply for this industrial sector. But according to our information, the four UK notified bodies have already taken initiatives, as I said before, to adapt to the post-Brexit scenario. The largest UK-notified body, BSI, is in the process of new designation in the Netherlands; this is expected to be completed in November. Another – SGS – already has local offices in Finland and Belgium, which could inherit certificates transferred from the UK. The two other notified bodies – UL and LRQA – have approached the same national authorities for a possible application, according to our information. So this is what the UK-notified bodies are doing. But of course, if any additional transitional period is agreed, then perhaps we might have some more time beyond 29 March.</p>
<p class="contents">There was also a question on the database. Work has so far been advancing, and again – not optimistically but realistically – we are in the timeframe. According to our plans, a first release of the plan for the implementation of the functional specification was accomplished by the legal deadline foreseen of 26 May this year, and the draft functional specification I expect to be ready by the end of this month (in one week). Again, here also we are in the timeframe. But I want to assure you, as I said a few sentences ago, that we are proactively monitoring the situation. I know that in some Member States there are some problems with the notified bodies, and I also practically discuss it with ministers and the governments of those countries, but for now we are on track and we are doing our best to face this challenge, but also to implement the new legal framework in a successful and timely manner.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-037-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96952.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20181025-10:00:54&amp;playerEndTime=20181025-10:01:00" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">La Présidente. – </span></span>  Le débat est clos.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td>Last updated: 8 April 2019</td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
